On May 23, 2018, we published revised versions of our Privacy Policy and User Agreements. Please read these updated terms and take some time to understand them. Your use of our services is subject to these revised terms.
Yes, I Agree.
Stocks To Buy Now

Blog


Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) to Execute Clinical Studies on Oral Forms of Nicotine Delivery Using DehydraTECH

  • LXRP’s DehydraTECH research funded by a partner that will provide $1 million, with an option for millions more
  • LXRP subsidiary Lexaria Nicotine LLC recently entered a definitive investment agreement to receive R&D funding in exchange for equity and licensing rights
  • In exchange, partner received minority equity interest in the subsidiary

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) will conduct a comprehensive series of clinical studies on oral forms of nicotine delivery utilizing its DehydraTECH absorption platform. Under an investment agreement by its wholly owned subsidiary, Lexaria Nicotine LLC, a partner will provide $1 million toward research on nicotine consumer products that use DehydraTECH (http://ibn.fm/9JkL7).

Lexaria’s partner will receive certain licensing rights to commercialize these DehydraTECH products exclusively in the United States and non-exclusively on a global scale. The partner, which will have the option to provide up to $12 million in additional funding to underwrite LXRP’s R&D, will pay LXRP a royalty on sales. The partner company will receive minority equity in the subsidiary and future rights to purchase a 100 percent interest in Lexaria Nicotine LLC at then-current fair market value, but not in LXRP itself.

In a news release, LXRP CEO Chris Bunka said, “This partnership will provide significant benefits to Lexaria Bioscience and its shareholders with a world-class R&D program and regulatory compliance process.”

Based in British Columbia, Canada, LXRP is a biotechnology company and drug delivery platform innovator that out-licenses its disruptive delivery technology, which promotes healthier ingestion methods. DehydraTECH is its proprietary absorption technology platform. LXRP holds a patent for oral delivery of all cannabinoids and has a growing IP portfolio, which includes 10 patents granted in the United States and Australia and more than 50 patent applications worldwide across 10 patent families.

For more information, visit the company’s website at www.LexariaBioscience.com

Last Tweets

Follow us: @Buy_Stocks_Now

From Our Blog

Spectrum Global Solutions Inc.’s (SGSI) Upcoming Agreement of Merger to Provide Unique Growth Opportunities

February 15, 2019

On February 7, Spectrum Global Solutions announced its entry into a definitive agreement of merger with WaveTech Global Inc. Upon completion of the merger, WaveTech will become the majority-controlling shareholder of Spectrum Global Solutions Representatives of the two companies announced that the merger will provide unique growth opportunities and tremendous value for shareholders Spectrum Global […]

Rotate your device 90° to view site.